Presentation Title

Repurposing Clinically Approved Drugs for the Treatment of Bacillus cereus, Surrogate for Bacillus anthracis

Faculty Mentor

Mikhail Martchenko

Start Date

17-11-2018 12:30 PM

End Date

17-11-2018 2:30 PM

Location

HARBESON 56

Session

POSTER 2

Type of Presentation

Poster

Subject Area

health_nutrition_clinical_science

Abstract

Of the numerous infectious diseases afflicting humans, Anthrax disease, caused by Bacillus anthracis, poses a major threat in its virulence and lack of effective treatment. The rapid rate of bacterial mutation as well as the lengthy drug approval process demonstrate the pressing demand for a treatment for B. anthracisinfections. The present study screened over 1,500 clinically approved drugs in an attempt to identify repurposable compounds against B. cereus, a relative strain that shares many physical and genetic characteristics with B. anthracis. Our study yielded five therapeutic candidates that successfully inhibited B. cereusgrowth. These drugs also exhibited varying levels of efficacy in broad spectrum experiments against several gram-positive and gram-negative bacterial strains. Through tests for efficacy of each drug onB. cereusin LB media, one of the five drugs indicated multi-fold enhanced efficacy compared to positive control on both solid and liquid media and exhibited synergistic characteristics of eradicating B. cereusin combination with a second molecule of interest on solid agar. The remarkable synergistic efficacy of combinatorial formulations with a third candidate in liquid media warrants further tests of greater dilutions of these formulations to achieve higher efficacy at decreased cytotoxicity levels. Our results suggest great potential for combination therapies and reveal a need for further testing of these compounds on B. anthracis. This multifaceted in vitrostudy of pre-approved drugs demonstrates the potential to repurpose these therapeutics as treatments for Anthrax disease in a time efficient manner to address a global health need.

This document is currently not available here.

Share

COinS
 
Nov 17th, 12:30 PM Nov 17th, 2:30 PM

Repurposing Clinically Approved Drugs for the Treatment of Bacillus cereus, Surrogate for Bacillus anthracis

HARBESON 56

Of the numerous infectious diseases afflicting humans, Anthrax disease, caused by Bacillus anthracis, poses a major threat in its virulence and lack of effective treatment. The rapid rate of bacterial mutation as well as the lengthy drug approval process demonstrate the pressing demand for a treatment for B. anthracisinfections. The present study screened over 1,500 clinically approved drugs in an attempt to identify repurposable compounds against B. cereus, a relative strain that shares many physical and genetic characteristics with B. anthracis. Our study yielded five therapeutic candidates that successfully inhibited B. cereusgrowth. These drugs also exhibited varying levels of efficacy in broad spectrum experiments against several gram-positive and gram-negative bacterial strains. Through tests for efficacy of each drug onB. cereusin LB media, one of the five drugs indicated multi-fold enhanced efficacy compared to positive control on both solid and liquid media and exhibited synergistic characteristics of eradicating B. cereusin combination with a second molecule of interest on solid agar. The remarkable synergistic efficacy of combinatorial formulations with a third candidate in liquid media warrants further tests of greater dilutions of these formulations to achieve higher efficacy at decreased cytotoxicity levels. Our results suggest great potential for combination therapies and reveal a need for further testing of these compounds on B. anthracis. This multifaceted in vitrostudy of pre-approved drugs demonstrates the potential to repurpose these therapeutics as treatments for Anthrax disease in a time efficient manner to address a global health need.